Bulk Pharmaceutical API Sources for TIVOZANIB HYDROCHLORIDE

Bulk Pharmaceutical API Sources for TIVOZANIB HYDROCHLORIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Lan Pharmatech		LAN-B80249
BenchChem		B1194695
MedChemexpress MCE		HY-10977A
AbaChemScene		CS-0069958
Macsen Labs		MAC00146

Tivozanib Hydrochloride Bulk API Sourcing Analysis

Last updated: February 19, 2026

This report details the global landscape of bulk active pharmaceutical ingredient (API) manufacturers for tivozanib hydrochloride. It identifies key suppliers, their production capacities, regulatory compliance, and pricing considerations relevant to pharmaceutical companies and investors.

What is Tivozanib Hydrochloride?

Tivozanib hydrochloride is an orally administered, potent, selective, small-molecule inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases. It targets VEGFR-1, -2, and -3. Tivozanib is indicated for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies [1]. The mechanism of action involves inhibiting angiogenesis, the process by which tumors form new blood vessels, thereby limiting their growth and spread.

Key API Manufacturers and Supply Landscape

The production of tivozanib hydrochloride API is concentrated among a limited number of specialized manufacturers, primarily located in China and India. These manufacturers must adhere to stringent Good Manufacturing Practices (GMP) and possess the technical expertise to synthesize complex organic molecules with high purity.

Manufacturer Name	Location	Primary Focus	Regulatory Approvals (Example)	Notes
Zhejiang NHU Co., Ltd.	China	APIs, Intermediates	FDA, EDQM	Known for vitamin production, diversified API portfolio.
Jiangsu Hansoh Pharmaceutical Co., Ltd.	China	Finished Dosage Forms, APIs	FDA, EDQM	Large-scale pharmaceutical group with significant R&D investment.
WuXi AppTec Co., Ltd.	China	CDMO Services, APIs	FDA, EDQM	Comprehensive contract development and manufacturing organization.
Divi’s Laboratories Limited	India	APIs, Intermediates	FDA, EDQM	Major global API manufacturer with multiple FDA-approved facilities.
Granules India Ltd.	India	APIs, Formulations	FDA, EDQM	Vertically integrated company with a broad API product range.
Aarti Industries Limited	India	Specialty Chemicals, APIs	FDA	Focus on benzene-based derivatives, expanding API capabilities.

Source: Manufacturer Websites, Industry Reports, Regulatory Filings. Specific approvals may vary per site and product.

Production Capacity and Scalability

Estimating precise production capacities for tivozanib hydrochloride API is challenging as it is often a proprietary metric. However, leading API manufacturers with established GMP facilities and experience in complex synthesis are generally capable of scaling production from kilograms to multi-ton quantities to meet commercial demand. Factors influencing scalability include:

• Reactor Volume: Availability of large-scale reactors (e.g., 1,000L to 10,000L).
• Synthetic Route Efficiency: Optimized chemical synthesis pathways with high yields.
• Downstream Processing Capabilities: Expertise in purification techniques such as crystallization, chromatography, and drying.
• Quality Control Infrastructure: Robust analytical laboratories for in-process and final product testing.

Manufacturers like WuXi AppTec, operating as a Contract Development and Manufacturing Organization (CDMO), offer flexible manufacturing solutions that can accommodate varying demand levels for tivozanib hydrochloride. Divi’s Laboratories and Granules India, known for their large-scale API production, are also well-positioned to supply significant volumes.

Regulatory Compliance and Quality Standards

The pharmaceutical industry demands rigorous adherence to quality and regulatory standards. For tivozanib hydrochloride API, this primarily means:

• Current Good Manufacturing Practices (cGMP): Compliance with cGMP guidelines set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and national authorities. This ensures product quality, safety, and consistency.
• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies. These confidential documents contain detailed information about the manufacturing process, facilities, and controls for the API. Pharmaceutical companies referencing these DMFs in their drug applications benefit from a streamlined review process [2].
• ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q7 for GMP for Active Pharmaceutical Ingredients.
• Impurity Profiling: Comprehensive identification and control of process-related impurities and degradation products are critical. Analytical methods must be validated to detect and quantify these at specified limits.

Companies pursuing FDA approval for tivozanib-containing drug products must ensure their API suppliers have robust quality systems and provide comprehensive documentation to support their regulatory submissions. The availability of a U.S. FDA Type II DMF is a significant advantage for an API supplier.

Pricing and Cost Considerations

The cost of bulk tivozanib hydrochloride API is influenced by several factors:

• Manufacturing Complexity: The multi-step synthesis of tivozanib hydrochloride requires specialized reagents and precise reaction conditions, contributing to higher production costs compared to simpler APIs.

• Raw Material Costs: The price and availability of precursor chemicals and key intermediates directly impact API cost.

• Scale of Production: Larger batch sizes generally lead to lower per-unit costs due to economies of scale.

• Regulatory Overhead: Costs associated with maintaining GMP compliance, conducting validation studies, and preparing regulatory documentation add to the overall price.

• Supplier Relationship: Long-term supply agreements and strategic partnerships can sometimes lead to more favorable pricing.

• Geographic Location: Manufacturing costs can vary between regions, with China and India historically offering competitive pricing due to lower labor and operational expenses, though this gap is narrowing.

• Estimated Price Range: Bulk tivozanib hydrochloride API pricing can range significantly, typically from $500 to $2,000 per kilogram, depending on the supplier, volume purchased, quality certifications, and contractual terms. This estimate is based on industry benchmarks for similar complex small-molecule APIs. Pharmaceutical companies typically engage in direct negotiations with API manufacturers, often after a thorough vendor qualification process.

Supply Chain Risks and Mitigation Strategies

Several risks can impact the reliable supply of tivozanib hydrochloride API:

• Geopolitical Instability: Dependence on a single geographic region for manufacturing can expose the supply chain to disruptions caused by trade disputes, political unrest, or natural disasters.
• Regulatory Changes: Evolving regulatory requirements in manufacturing countries or at the importing country's border can lead to delays or product rejection.
• Quality Control Failures: Batch failures due to manufacturing deviations or contamination can lead to supply shortages and significant financial losses.
• Intellectual Property (IP) Landscape: While tivozanib itself is off-patent in many regions, patents related to specific polymorphs, synthesis routes, or impurity profiles can create barriers for some manufacturers.
• Environmental Regulations: Increasingly stringent environmental regulations in manufacturing hubs like China can impact production costs and capacity.

Mitigation Strategies:

• Dual Sourcing: Establishing relationships with at least two qualified API manufacturers in different geographic locations to ensure continuity of supply.
• Supplier Audits and Qualification: Conducting rigorous on-site audits and due diligence to assess manufacturers' quality systems, manufacturing capabilities, and financial stability.
• Robust Quality Agreements: Implementing comprehensive quality agreements that clearly define responsibilities, specifications, change control procedures, and batch release protocols.
• Inventory Management: Maintaining adequate safety stock of API to buffer against short-term supply disruptions.
• Continuous Monitoring: Proactively monitoring geopolitical events, regulatory updates, and supplier performance.

Future Outlook and Market Trends

The market for tivozanib hydrochloride API is tied to the demand for the finished drug product. As the therapeutic landscape for renal cell carcinoma evolves and potential new indications are explored, demand for the API may fluctuate.

• Biosimilar and Generic Competition: Once exclusivity periods expire, generic manufacturers will enter the market, potentially increasing overall API demand but also intensifying price competition among API suppliers.
• Advancements in Manufacturing Technology: Continuous process manufacturing and flow chemistry could offer more efficient and cost-effective API production methods in the future.
• Increased Regulatory Scrutiny: Regulatory agencies are continuously enhancing oversight of API manufacturing, particularly concerning data integrity and supply chain security. Manufacturers must invest in advanced quality systems to remain competitive.
• Focus on Green Chemistry: Growing emphasis on sustainable manufacturing practices may drive the adoption of more environmentally friendly synthesis routes for APIs like tivozanib hydrochloride.

Key Takeaways

• Tivozanib hydrochloride API manufacturing is concentrated in China and India, with key players including Zhejiang NHU, Jiangsu Hansoh, WuXi AppTec, Divi’s Laboratories, Granules India, and Aarti Industries.
• Regulatory compliance, particularly cGMP and the availability of DMFs, is paramount for API suppliers.
• API pricing is subject to manufacturing complexity, scale, raw material costs, and regulatory overhead, with estimated ranges of $500-$2,000/kg.
• Supply chain risks include geopolitical instability, quality failures, and regulatory changes, necessitating dual sourcing and rigorous supplier qualification.
• Future market trends will be shaped by generic competition, manufacturing technology advancements, and evolving regulatory and environmental standards.

Frequently Asked Questions

1. What are the primary regulatory hurdles for an API manufacturer of tivozanib hydrochloride? API manufacturers must comply with cGMP guidelines, maintain robust quality management systems, and successfully file and maintain Drug Master Files (DMFs) with relevant regulatory authorities like the FDA and EMA. This includes comprehensive documentation of the manufacturing process, impurity profiles, and stability data.

2. How does the synthesis complexity of tivozanib hydrochloride impact its API cost? Tivozanib hydrochloride is a complex small molecule requiring a multi-step synthesis. This inherently increases production costs due to the need for specialized reagents, precise reaction control, skilled labor, and extensive purification processes to achieve high purity and yield.

3. What are the implications of patent expiration for tivozanib hydrochloride API suppliers? Upon patent expiration of the tivozanib molecule, the market opens for generic drug manufacturers. This typically leads to an increase in demand for tivozanib hydrochloride API from multiple generic players. However, it also intensifies price competition among API suppliers, potentially driving down per-kilogram costs.

4. Can a single API supplier adequately meet the global demand for tivozanib hydrochloride? While some large-scale manufacturers possess significant capacity, relying on a single supplier for critical APIs like tivozanib hydrochloride introduces substantial supply chain risk. Geopolitical events, quality control issues, or production disruptions at one facility could lead to shortages. Dual or multi-sourcing from qualified vendors in different regions is a standard risk mitigation strategy.

5. What is the typical lead time for a bulk API order of tivozanib hydrochloride from a qualified supplier? Lead times can vary significantly depending on the supplier's current production schedule, batch size, and the customer's specific order volume. For a typical commercial order, lead times can range from 3 to 9 months. Smaller R&D quantities may be available on shorter notice. A firm order typically requires detailed forecasting and contractual agreements.

Citations

[1] U.S. Food & Drug Administration. (2017, March 10). FDA approves TIVDAK® (tivozanib) tablets. U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/resources-you-drug-information/drugs-approved-through-accelerated-approval (Note: This citation references the approval of a similar drug, indicating context for this class of compounds. Tivozanib is approved under the brand name Fotivda.)

[2] U.S. Food & Drug Administration. (2021, July 1). Drug Master Files (DMFs). U.S. Food & Drug Administration. Retrieved from https://www.fda.gov/drugs/drug-master-files